Table 5.

Oligonucleotide primers used in this study

Primer	Sequence 5 '- 3'
F/cea7-BamHI	GGATCCATGAGCGGTGGAGATGGACG
R/cei7-PstI	CTGCAGTCAGCCCTGTTTAAATCC
F/btuB-219-XbaI	GGCTCTAGAAAACGGTGCCATCATACTTTG
R/btuB+242-HindIII	GGCAAGCTTATCATTGTAAAGCATCCACAATAG
F/btuB-767	GTTCACCGTTGCTCGATACC
R/btuB-1087	TCAGATAGATGCCGGTATTACG
F/btuB-431-XbaI	GCTCTAGAACGGGATTATTACGC
F/btuB-671-XbaI	GCTCTAGATCATCTCTTTCCC
F/btuB-1043-XbaI	GCTCTAGACCGCTGCGCGGA
R/lacZ	TTATTTTTGACACCAGACC
F/gadA-176	GATCGCCCGAACAGCAA
R/gadA+77	CGTGAATCGAGTAGTTC
F/gadB-173	AATAACAGCATAAAACA
R/gadB+77	CGTGAATCGAGTAGTTCC
F/pal-XbaI	TCTAGAGAGGCGTACAAGTTCTG
R/pal-HindIII	AAGCTTATCATTTCAATGATTCCTTTAC
F/gadX-BamHI	GGATCCATGCAACCACTACATGG
R/gadX-PstI	CTGCAGCTATAATCTTATTCCTT
F/gadX-393	TATACCGCTGCTTCTGAACG
R/gadX-726	TCGCTCCTGATACTCTGTGG
F/rrsA-483	CGTTACCCGCAGAAGAAGC
R/rrsA-808	GTGGACTACCAGGGTATCTAATCC

The underlined letters indicate restriction sites.